title: Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.
abstract: The use of chemotherapeutic agents, such as anthracycline or trastuzumab, in oncology is limited by their cardiac toxicity. Recent experimental studies suggest that recombinant human erythropoietin (rhEPO) can be considered as a protective agent because its administration protects against cardiac ischemic injury, improving functional recovery, and reducing cell death. The aim of this study was to investigate whether pretreatment by rhEPO protects against acute cardiotoxicity induced by doxorubicin and trastuzumab, using the isolated rat heart model. Rats were treated with rhEPO (5000 IU/kg, intraperitoneally [i.p.]) or vehicle. One hour later, hearts were isolated and retrogradely perfused at constant flow. Following 20 mins of stabilization, hearts were perfused for 60 mins with modified-Krebs solution containing 6 mg/l doxorubicin or 10 mg/l trastuzumab. Hearts receiving doxorubicin were paced; those receiving trastuzumab were unpaced. Control hearts were perfused with modified-Krebs solution only. Doxorubicin exposure decreased left ventricular developed pressure (LVDP; approximately -40% of baseline) and increased end diastolic pressure (EDP; approximately +390% of baseline) and coronary perfusion pressure (CPP; approximately +70% of baseline). Incidence of ventricular tachycardia or fibrillation (VT/VF) was also significantly enhanced (86% vs. 0% in control group). Trastuzumab exposure increased CPP and EDP (approximately +70% of baseline for the both) without affecting LVDP. Prior rhEPO treatment significantly prevented doxorubicin-induced deleterious effects on LVDP, EDP, and VT/VF incidence. rhEPO administration also prevented trastuzumab-induced deleterious effects on CPP and EDP. This study shows that pretreatment by rhEPO protects myocardium against functional damage and electrophysiologic injury induced by acute doxorubicin or trastuzumab exposure. Further investigations are required to elucidate the precise mechanisms involved.
authors.affiliation: Laboratoire HP2, Hypoxie Physio-Pathologie Respiratoire et Cardiovasculaire, EA 3745, Faculté de Medicine-Pharmacie, Universite Grenoble I, France.
authors.forename: Amandine
authors.initials: A
authors.lastname: Ramond
authors.forename: Eugénie
authors.initials: E
authors.lastname: Sartorius
authors.forename: Mireille
authors.initials: M
authors.lastname: Mousseau
authors.forename: Christophe
authors.initials: C
authors.lastname: Ribuot
authors.forename: Marie
authors.initials: M
authors.lastname: Joyeux-Faure
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000633:toxicity*; D001794:Blood Pressure / Q000187:drug effects; D004317:Doxorubicin / Q000633:toxicity*; D004921:Erythropoietin / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D066298:In Vitro Techniques; D020011:Protective Agents / Q000627:therapeutic use; D051381:Rats; D011994:Recombinant Proteins; D000068878:Trastuzumab; D014693:Ventricular Fibrillation / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D020011:Protective Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D004317:Doxorubicin; D000068878:Trastuzumab